川宁生物(301301) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 reached ¥1,260,838,882.99, an increase of 8.31% compared to the same period last year, and a year-to-date revenue of ¥4,456,265,553.38, up 24.43% year-on-year[5]. - Net profit attributable to shareholders for Q3 2024 was ¥309,614,433.32, representing a 24.20% increase year-on-year, with a year-to-date net profit of ¥1,075,918,531.82, up 68.07%[5]. - Basic earnings per share for Q3 2024 was ¥0.14, an increase of 27.27% compared to the same period last year, with a year-to-date EPS of ¥0.48, up 65.52%[5]. - Total operating revenue for Q3 2024 reached ¥4,456,265,553.38, an increase of 24.4% compared to ¥3,581,333,354.27 in the same period last year[19]. - Net profit for Q3 2024 was ¥1,075,957,079.13, representing a significant increase of 68% from ¥640,149,589.72 in Q3 2023[20]. - The net profit for the third quarter of 2024 was CNY 1,075,957,079.13, an increase from CNY 640,149,589.72 in the same period last year, representing a growth of approximately 68%[21]. - The net profit attributable to shareholders of the parent company was CNY 1,075,918,531.82, compared to CNY 640,149,778.46 in the previous year, reflecting a year-over-year increase of about 68%[21]. - The basic and diluted earnings per share for the third quarter were both CNY 0.48, up from CNY 0.29 in the same quarter last year, indicating a growth of approximately 65%[21]. Assets and Liabilities - Total assets as of the end of Q3 2024 were ¥10,551,376,493.93, reflecting a 4.07% increase from the end of the previous year[5]. - Shareholders' equity attributable to the parent company was ¥7,570,369,941.77, an increase of 8.76% compared to the end of the previous year[5]. - Current liabilities decreased to ¥1,996,994,497.66 from ¥2,535,717,317.94, a reduction of 21.2%[18]. - Long-term borrowings increased to ¥392,999,999.99 from ¥357,333,333.00, reflecting a rise of 10%[18]. - Total current assets included cash and cash equivalents of ¥624,172,142.98, down from ¥760,935,778.29 at the beginning of the period[16]. - Cash and cash equivalents at the end of the period were CNY 618,915,346.89, down from CNY 1,029,201,761.89 at the end of the same period last year, a decline of about 39.9%[25]. Cash Flow - The company reported a net cash flow from operating activities of ¥875,259,669.44, which is a decrease of 20.62% year-on-year[5]. - Net cash flow from operating activities decreased by 20.62% to ¥875,259,669.44, primarily due to a reduction in discounts and an increase in accounts receivable by ¥512 million[12]. - Net cash flow from investing activities improved by 45.61% to -¥111,482,634.10, reflecting a decrease in cash payments for fixed assets and project costs[12]. - Net cash flow from financing activities decreased by 39.93% to -¥904,130,391.82, as repayments of due loans decreased during the period[12]. - Cash inflows from operating activities totaled CNY 3,165,660,715.72, compared to CNY 2,913,652,957.60 in the previous year, marking an increase of about 8.7%[23]. - The net cash flow from operating activities was CNY 875,259,669.44, down from CNY 1,102,683,880.83 in the same period last year, a decrease of approximately 20.6%[24]. - The company reported cash outflows from financing activities of CNY 1,620,322,311.82, compared to CNY 1,991,855,874.57 in the previous year, a decrease of approximately 18.7%[24]. - The company received CNY 690,000,000.00 in borrowings during the quarter, an increase from CNY 481,800,000.00 in the same period last year, representing a growth of about 43.3%[24]. - The company reported cash inflows from investment activities of CNY 201,145,426.03, compared to CNY 0.00 in the previous year, indicating new investment activity[24]. Operational Metrics - Accounts receivable increased by 37.72% to ¥1,030,260,734.68 due to revenue growth, while inventory decreased by 46.50% to ¥896,831,183.83[9]. - The company recorded a significant increase in prepayments by 637.90% to ¥331,334,519.69, attributed to seasonal procurement[9]. - The company has increased its long-term equity investments by 139.08% to ¥16,218,376.88, indicating a strategic focus on joint ventures[9]. - The company plans to expand its agricultural land leasing, resulting in a 164.98% increase in right-of-use assets to ¥507,499,991.03[10]. - Sales expenses increased by 33.78% to ¥19,570,247.05 due to higher personnel costs and marketing activities[11]. - Research and development expenses for Q3 2024 were ¥44,066,130.04, up from ¥39,057,245.56, marking an increase of 12.9%[20]. - Inventory decreased significantly to ¥896,831,183.83 from ¥1,676,440,163.24, indicating improved inventory management[16]. Other Financial Metrics - Investment income improved by 38.19% to -¥7,158,473.66 as forward exchange loss decreased during the reporting period[11]. - Fair value changes resulted in a gain of ¥644,500.00, a 135.44% increase compared to the previous year, due to reduced losses from undelivered forward foreign exchange contracts[11]. - Credit impairment losses decreased significantly by 1,182.16% to ¥2,330,553.05, attributed to the recovery of previously written-off debts[11]. - Deferred tax assets increased to ¥28,264,505.59 from ¥21,653,051.13, showing a growth of 30.5%[17]. Shareholder Information - The company’s major shareholder, Sichuan Kelun Pharmaceutical Co., Ltd., holds 70.49% of the shares, indicating strong control over the company[13]. Audit Status - The company has not undergone an audit for the third quarter report[25].